Eli Lilly agreed to acquire AtaiBeckley, paying $2.8 billion upfront and up to $3.8 billion including milestone-based contingent value rights. The deal gives Lilly an entry point into psychedelic-based psychiatry, with AtaiBeckley’s lead program BPL-003 (mebufotenin benzoate) already in Phase 2b testing for treatment-resistant depression. The acquisition expands Lilly’s neuroscience ambitions beyond its core cardiometabolic franchise and adds a late-stage psychiatric asset with in-clinic dosing data showing symptom improvements beginning on day two and extending through follow-up periods. For Lilly, the move also reflects a broader shift by large pharma toward developing centrally acting, high-regulatory-complexity therapies. For the AtaiBeckley program specifically, investors will focus on how Lilly navigates the clinical and regulatory pathway for psychedelic medicines and whether the pivotal plan can translate Phase 2b signals into Phase 3-readiness outcomes.